COVID-19 Clinical Trial
Official title:
Opportunistic Screening for Asymptomatic Left Ventricular Dysfunction in COVID-19 Survivors
Coronavirus Disease 2019 (COVID-19) emerged in December 2019, and in mere few months has
resulted in a pandemic of viral pneumonia. Substantial proportion of patients with COVID-19
have biochemical evidence of myocardial injuries during the acute phase. Possible mechanisms
including acute coronary events, cytokine storm, and COVID-19 related myocarditis, have been
postulated for the cardiac involvement in COVID-19. It is uncertain whether COVID-19
survivors are at risk cardiac dysfunction including cardiac arrhythmia and heart failure.
The prospective screening study aims to evaluate the possible latent effects from COVID-19 in
COVID-19 survivors. COVID-19 survivors 4-6 weeks after hospital discharge will be recruited
from the Infectious Disease clinic, Queen Mary Hospital with standard 12-lead
electrocardiogram, serum troponin, NT-proBNP, and standard transthoracic echocardiogram.
The outcome measures include (1) new onset cardiac arrhythmia, (2) N Terminal (NT)-proBNP
elevation above the diagnostic range of heart failure, and (3) newly detected left
ventricular dysfunction.
Coronavirus Disease 2019 (COVID-19) emerged in December 2019, and in mere few months has
resulted in a pandemic of viral pneumonia. As of April 2020, over 2 million populations were
infected and more than 150,000 deaths globally. In the initial report from Wuhan, China, up
to 27.8% COVID19 patients had an elevated troponin level indicating myocardial damage during
the index hospitalization for COVID. This is nearly 10-folded higher than that of other
common viral illnesses such as influenza (2.9%). Possible mechanisms including acute coronary
events, cytokine storm, and COVID-19 related myocarditis, have been postulated for the
cardiac involvement in COVID-19. Nonetheless, it is unknown whether COVID-19 survivors are at
risk cardiac dysfunction including cardiac arrhythmia and heart failure.
The prospective screening study aims to evaluate the possible latent effects from COVID-19 in
COVID-19 survivors. COVID-19 survivors 4-6 weeks after hospital discharge will be recruited
from the Infectious Disease clinic, Queen Mary Hospital. Standard 12-lead electrocardiogram,
serum troponin, NT-proBNP, and standard transthoracic echocardiogram will be performed for
COVID-19 survivors.
The outcome measures include (1) new onset cardiac arrhythmia, (2) NT-proBNP elevation above
the diagnostic range of heart failure, and (3) newly detected left ventricular dysfunction.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT06065033 -
Exercise Interventions in Post-acute Sequelae of Covid-19
|
N/A | |
| Completed |
NCT06267534 -
Mindfulness-based Mobile Applications Program
|
N/A | |
| Completed |
NCT05047601 -
A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05323760 -
Functional Capacity in Patients Post Mild COVID-19
|
N/A | |
| Recruiting |
NCT04481633 -
Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection
|
N/A | |
| Completed |
NCT04537949 -
A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults
|
Phase 1/Phase 2 | |
| Completed |
NCT04612972 -
Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru
|
Phase 3 | |
| Recruiting |
NCT05494424 -
Cognitive Rehabilitation in Post-COVID-19 Condition
|
N/A | |
| Active, not recruiting |
NCT06039449 -
A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2
|
Phase 3 | |
| Enrolling by invitation |
NCT05589376 -
You and Me Healthy
|
||
| Completed |
NCT05158816 -
Extracorporal Membrane Oxygenation for Critically Ill Patients With COVID-19
|
||
| Recruiting |
NCT04341506 -
Non-contact ECG Sensor System for COVID19
|
||
| Completed |
NCT04384445 -
Zofin (Organicell Flow) for Patients With COVID-19
|
Phase 1/Phase 2 | |
| Completed |
NCT04512079 -
FREEDOM COVID-19 Anticoagulation Strategy
|
Phase 4 | |
| Completed |
NCT05975060 -
A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants.
|
Phase 2/Phase 3 | |
| Active, not recruiting |
NCT05542862 -
Booster Study of SpikoGen COVID-19 Vaccine
|
Phase 3 | |
| Terminated |
NCT05487040 -
A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease
|
Phase 1 | |
| Withdrawn |
NCT05621967 -
Phonation Therapy to Improve Symptoms and Lung Physiology in Patients Referred for Pulmonary Rehabilitation
|
N/A | |
| Terminated |
NCT04498273 -
COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80
|
Phase 3 | |
| Active, not recruiting |
NCT06033560 -
The Effect of Non-invasive Respiratory Support on Outcome and Its Risks in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-Related Hypoxemic Respiratory Failure
|